AnaptysBio shares surge after Delaware court dismisses Tesaro contract claim
Updated
Updated · MarketWatch · Apr 27
AnaptysBio shares surge after Delaware court dismisses Tesaro contract claim
13 articles · Updated · MarketWatch · Apr 27
Shares of AnaptysBio jumped 14% to $67.28, hitting a five-year high of $70.22 following the court decision.
The Delaware Chancery Court dismissed Tesaro's anticipatory breach of contract claim, but Tesaro's separate declaratory judgment claim against AnaptysBio remains active.
The legal dispute began over a 2014 collaboration agreement, with AnaptysBio's breach of contract suit against Tesaro scheduled for trial in July.
Is AnaptysBio's stock surge justified ahead of its high-stakes trial in July?
How will this court ruling reshape future collaboration deals in the biotech industry?
Could AnaptysBio's legal fight inadvertently hinder Jemperli's maximum commercial potential?
Can AnaptysBio's royalty-only business model create sustainable long-term shareholder value?
After its legal setback, what is GSK's new strategy for the Jemperli partnership?